Vir Biotech's HBV Candidates Show Positive Safety Profiles

  • Vir Biotechnology Inc VIR has announced new data from its ongoing Phase 2 trials of VIR-2218 and Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus (HBV) infection. 
  • The results were presented at the European Association for the Study of the Liver International Liver Congress 2021.
  • Data demonstrated an encouraging safety profile and the potential durable response of VIR-2218, an investigational small interfering ribonucleic acid, through 48 weeks. 
  • In a separate analysis evaluating VIR-2218 in combination with pegylated interferon alfa for 12 weeks, a more rapid and substantial HBsAg decline was observed in the co-administration cohort compared to VIR-2218 alone. 
  • The treatment regimen resulted in no new safety signals.
  • Additionally, two new analyses from the Phase 1 trial of VIR-3434 showed no safety signals in healthy volunteers dosed with up to 3,000 mg. 
  • The company plans to start a VIR-3434 - VIR-2218 combination trial in the second half of 2021.
  • Price Action: VIR shares are down 6.9% at $46.17 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsHepatits B
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!